Transcenta Holding Limited (HK:6628)
:6628
Want to see HK:6628 full AI Analyst Report?
6628 Stock Chart & Stats
HK$2.25
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.25
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.30 - HK$5.80
Previous CloseN/A
Volume339.50K
Average Volume (3M)1.29M
Market Cap
HK$663.41M
Enterprise ValueHK$659.52M
Total Cash (Recent Filing)HK$45.81M
Total Debt (Recent Filing)HK$210.14M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding455,375,000
10 Day Avg. Volume1,161,500
30 Day Avg. Volume1,285,964
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.28
Price to Sales (P/S)108.90
P/FCF Ratio-5.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.76
Revenue Forecast (FY)HK$15.24M
Bulls Say, Bears Say
Bulls Say
Vertical Integration And Pipeline BreadthOwning R&D through manufacturing and commercialization creates a durable operational advantage: tighter CMC control, faster candidate progression, and potential margin capture across the value chain. A pipeline spanning oncology and immunology diversifies long-term revenue pathways and reduces single-product dependence.
Improving Leverage ProfileA falling debt-to-equity ratio meaningfully reduces refinancing and interest-rate risk, preserving financial flexibility. Manageable leverage gives the company runway to fund clinical programs and commercialization efforts without immediate heavy debt servicing, supporting survival through multi‑period development timelines.
Improving Operating Cash Outflow TrendA reduction in operating cash outflow signals initial progress toward cash efficiency and program prioritization. Sustained reductions can extend runway and lower near-term funding needs, making it easier to execute clinical milestones and commercial initiatives while working toward positive cash generation.
Bears Say
Material Revenue ContractionSubstantial and persistent revenue decline erodes scale needed to absorb fixed R&D and manufacturing costs, weakens pricing power, and reduces internal funding for development. Without a clear revenue recovery, commercial traction and ability to fund pipelines internally remain impaired over multiple quarters.
Negative Gross Profit OutcomeA swing to negative gross profit is a structural red flag: unit economics or COGS have worsened, making scalable profitability unlikely without major fixes. This undermines margin sustainability and means operating leverage cannot deliver profits until core product economics are corrected.
Persistent Cash Burn And Funding DependenceConsistent negative operating and free cash flow forces reliance on external capital, creating dilution risk and exposure to capital-market access. This structural funding dependence constrains strategic options, heightens execution risk, and can delay or derail long-term R&D and commercialization plans if financing costs rise or markets tighten.
Transcenta Holding Limited News
6628 FAQ
What was Transcenta Holding Limited’s price range in the past 12 months?
Transcenta Holding Limited lowest stock price was HK$1.30 and its highest was HK$5.80 in the past 12 months.
What is Transcenta Holding Limited’s market cap?
Transcenta Holding Limited’s market cap is HK$663.41M.
When is Transcenta Holding Limited’s upcoming earnings report date?
Transcenta Holding Limited’s upcoming earnings report date is Sep 02, 2026 which is in 77 days.
How were Transcenta Holding Limited’s earnings last quarter?
Transcenta Holding Limited released its earnings results on Mar 30, 2026. The company reported -HK$0.241 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.241.
Is Transcenta Holding Limited overvalued?
According to Wall Street analysts Transcenta Holding Limited’s price is currently Overvalued.
Does Transcenta Holding Limited pay dividends?
Transcenta Holding Limited does not currently pay dividends.
What is Transcenta Holding Limited’s EPS estimate?
Transcenta Holding Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transcenta Holding Limited have?
Transcenta Holding Limited has 455,375,000 shares outstanding.
What happened to Transcenta Holding Limited’s price movement after its last earnings report?
Transcenta Holding Limited reported an EPS of -HK$0.241 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.735%.
Which hedge fund is a major shareholder of Transcenta Holding Limited?
Currently, no hedge funds are holding shares in HK:6628
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Transcenta Holding Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
278.57%
12-Months-Change
Fundamentals
Return on Equity
-28.13%
Trailing 12-Months
Asset Growth
-19.36%
Trailing 12-Months
Company Description
Transcenta Holding Limited
Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacturing, and commercialization of therapeutic agents within the People's Republic of China and the United States. The company boasts a comprehensive pipeline of drug candidates. In oncology, its key developments include: MSB2311, a humanized PD-L1 monoclonal antibody, currently in Phase Ib/IIa trials for various solid tumors, particularly those with high tumor mutational burden (TMB-H). TST001, a humanized claudin 18.2 monoclonal antibody undergoing Phase II clinical development for solid tumors, such as gastric cancer. TST005, a bifunctional PD-L1/TGF-ß antibody in Phase Ia clinical trials for solid tumors, including certain types of lung cancer. TST010, an antibody designed to target regulatory T cells, aiming to bolster T cell-mediated anti-tumor activity. TST003, an antibody addressing a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells exhibiting a mesenchymal phenotype. TST006, a bispecific antibody targeting both claudin 18.2 and PD-L1. TST008, a trifunctional antibody that combines a MASP2 antibody with a truncated transmembrane activator and CAML interactor protein. MSB0254, a humanized VEGFR-2 monoclonal antibody also in Phase Ib/IIa clinical studies for solid tumors. Beyond cancer, Transcenta is advancing: TST002 (Blosozumab), a humanized sclerostin monoclonal antibody for the treatment of osteoporosis. TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) monoclonal antibody intended for IgA kidney diseases. The company has forged collaboration agreements with prominent organizations, including Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. Founded in 2010 as MabSpace International Limited, the entity adopted the name Transcenta Holding Limited in June 2019. Its corporate headquarters are located in Suzhou, People's Republic of China.
Technical Analysis
Genor Biopharma Holdings Limited
―
Alphamab Oncology
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―
Options Prices
Currently, No data available
---